Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan hydrochloride (II) + oxaliplatin + 5-fluorouracil + leucovorin versus nab-paclitaxel + gemcitabine as first-line treatment for metastatic pancreatic cancer
CTR20254276Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nanoliposomal irinotecan, oxaliplatin, fluorouracil, folinic acid, paclitaxel and 1 more in pancreatic cancer (PC) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: overall survival. Started Dec 2025; status: active.
02
Drugs
nanoliposomal irinotecanoxaliplatinfluorouracilfolinic acidpaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20254276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254276.